Aclarion, Inc. (NASDAQ:ACON) Sees Large Increase in Short Interest

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 42,256 shares, an increase of 142.6% from the November 30th total of 17,416 shares. Approximately 6.3% of the company’s stock are sold short. Based on an average trading volume of 114,351 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 114,351 shares, the short-interest ratio is currently 0.4 days. Approximately 6.3% of the company’s stock are sold short.

Aclarion Stock Down 1.7%

Shares of Aclarion stock opened at $5.89 on Friday. Aclarion has a 12-month low of $5.55 and a 12-month high of $3,499.51. The stock has a 50 day moving average price of $6.74 and a two-hundred day moving average price of $7.25. The stock has a market capitalization of $3.95 million, a P/E ratio of -0.39 and a beta of 1.43.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. Sell-side analysts anticipate that Aclarion will post -263.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.